Myricetin 3-O-galactoside

Synonyms: 杨梅素 3-O-半乳糖苷
Myricetin 3-O-galactoside 是一种口服有效的糖苷衍生物,具有多种生物活性:它通过抑制尿路致病性大肠杆菌 (UPEC) 的黏附来缓解小鼠尿路感染,通过抑制 NO(主要是 iNOS)合成发挥外周镇痛和抗炎活性,通过抑制 cAMP/PKA/CREB 通路并激活 ERK1/2 信号双重下调 MITF 的表达和活性从而发挥抗黑色素生成作用,并可抑制 DHHP 和黄嘌呤氧化酶 (xanthine oxidase),具有抗氧化、抗脂质过氧化和抗突变活性。
产品编号: MS-B77790 纯度: 99.27% CAS No.: 15648-86-9 分子式: C21H20O13 分子量: 480.38
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价

产品描述

Myricetin 3-O-galactoside 是一种口服有效的糖苷衍生物,具有多种生物活性:它通过抑制尿路致病性大肠杆菌 (UPEC) 的黏附来缓解小鼠尿路感染,通过抑制 NO(主要是 iNOS)合成发挥外周镇痛和抗炎活性,通过抑制 cAMP/PKA/CREB 通路并激活 ERK1/2 信号双重下调 MITF 的表达和活性从而发挥抗黑色素生成作用,并可抑制 DHHP 和黄嘌呤氧化酶 (xanthine oxidase),具有抗氧化、抗脂质过氧化和抗突变活性。

生物实验数据

生物活性 Myricetin 3-O-galactoside is an orally effective glycoside derivative with multiple biological activities: it alleviates urinary tract infection in mice by inhibiting the adhesion of uropathogenic Escherichia coli (UPEC), exerts peripheral analgesic and anti-inflammatory activities by inhibiting NO (mainly iNOS) synthesis, exerts anti-melanogenic effects by dually downregulating MITF expression and activity through inhibiting the cAMP/PKA/CREB pathway and activating ERK1/2 signaling, and inhibits DHHP and xanthine oxidase, thereby exhibiting antioxidant, anti-lipid peroxidation, and antimutagenic activities.
IC50 & Target ACE:20.3 μM
体外研究
(In Vitro)

Myricetin 3-O-galactoside (50 μM; 3 h) 会在孵育 3 h 后破坏 E. coli CFT073 表面的菌毛结构。
Myricetin 3-O-galactoside (50 μM; 12 h) 可抑制 UPEC CFT073 与 E. coli 25922 对人膀胱癌 T24 细胞的黏附和侵袭作用。
Myricetin 3-O-galactoside (12.5-100 μM; 2 h) 可呈剂量依赖性地抑制 FITC 标记的 UPEC CFT073 以及大肠杆菌 25922 与人膀胱癌 T24 细胞的黏附作用。
Myricetin 3-O-galactoside 可下调 UPEC CFT073 中 fimA、fimH、papF 和 csgA 黏附素基因的表达。
Myricetin 3-O-galactoside (25-100 μM) 以剂量依赖的方式降低 UPEC CFT073 中 FimA 和 FimH 的蛋白表达水平。
Myricetin 3-O-galactoside 可下调人膀胱癌 T24 细胞中 α3 整合素和 β1 整合素基因的表达。
Myricetin 3-O-galactoside (1-20 μM; 24 h) 在 24 h 后、浓度不超过 10 μM 时不会降低 B16F10 细胞活力,但在 20 μM 浓度下会导致细胞活力显著下降。
Myricetin 3-O-galactoside (1-10 μM; 24 h) 可浓度依赖性地抑制 α-MSH 刺激的 B16F10 细胞中的酪氨酸酶活性,处理时长为 24 h。
Myricetin 3-O-galactoside (1-10 μM; 24 h) 可浓度依赖性地降低经 α-MSH 刺激的 B16F10 细胞中的黑色素含量,处理时长为 24 h。
Myricetin 3-O-galactoside (1-10 μM; 24 h) 可浓度依赖性地下调经 α-MSH 刺激的 B16F10 细胞中酪氨酸酶、MITF、TRP-1 和 TRP-2 的 mRNA 表达,处理时长为 24 h。
Myricetin 3-O-galactoside (1-10 μM; 24 h) 可浓度依赖性地下调酪氨酸酶、MITF、TRP-1 和 TRP-2 的蛋白水平;抑制 cAMP/PKA/CREB 及 Wnt/β-catenin 信号通路;并在处理 24 h 后上调 α-MSH 刺激的 B16F10 细胞中 ERK1/2 的磷酸化水平。
Myricetin 3-O-galactoside (1-10 μM; 24 h) 可浓度依赖性地降低经 α-MSH 刺激的 B16F10 细胞中的 cAMP 水平,处理时长为 24 h。
Myricetin 3-O-galactoside (10 μM; 24 h) 可在处理 24 小时后恢复 α-MSH 刺激的 B16F10 细胞中 ERK1/2 的激活,使活化型 ERK1/2 占总 ERK 蛋白的比例提升至 25.38%。
Myricetin 3-O-galactoside (50-800 μg/mL; 72 h) 对人慢性粒细胞白血病 K562 细胞具有细胞毒性,其 IC50 为 220 μg/mL。
Myricetin 3-O-galactoside (110-440 μg/mL; 4 h) 可抑制 H2O2 诱导的人慢性粒细胞白血病 K562 细胞的脂质过氧化,其 IC50 为 160 μg/mL,在 440 μg/mL 浓度下抑制率可达 92%。
Myricetin 3-O-galactoside (1-100 μg/mL; 30 min) 是无细胞体系中的 DPPH 自由基清除剂,其 IC50 为 2.3 μg/mL,在 100 μg/mL 浓度下清除活性可达 88%。
Myricetin 3-O-galactoside (100-300 μg/mL; 30 min) 在无细胞体系中,100 μg/mL 浓度下可抑制黄嘌呤氧化酶活性达 57%,但在 200 μg/mL 和 300 μg/mL 浓度下表现出促氧化效应。
Myricetin 3-O-galactoside (220 μg/mL; 36 h) 可在经 H2O2 胁迫的人慢性粒细胞白血病 K562 细胞中调控抗氧化、DNA 修复、凋亡及氧化应激响应基因的表达;相较于仅经 H2O2 胁迫的细胞,其关键变化包括硫氧还蛋白过氧化物酶 (AOE372) 表达上调,谷胱甘肽过氧化物酶 1 (GPX1) 表达下调,以及着色性干皮病互补群 C (XPC)、DNA 连接酶 4 (LIG4)、14 kD 复制蛋白 (RPA3)、增殖细胞核抗原 (PCNA) 和 DNA 损伤诱导转录本 3 (DDIT3) 的表达降低。

Cell Viability Assay

Cell Line: B16F10 murine melanoma cells
Concentration: 1, 5, 10 and 20 μM
Incubation Time: 24 h
Result: Showed no significant decrease in cell viability at 1, 5, or 10 μM.
Caused a significant decrease in cell viability at 20 μM.

Real Time qPCR

Cell Line: α-MSH-stimulated B16F10 murine melanoma cells
Concentration: 1, 5 and 10 μM
Incubation Time: 24 h
Result: Reduced mRNA levels of tyrosinase, MITF, TRP-1, and TRP-2 in a concentration-dependent manner, with significant decreases observed for all four genes at all tested concentrations.

Western Blot Analysis

Cell Line: α-MSH-stimulated B16F10 murine melanoma cells
Concentration: 1, 5 and 10 μM
Incubation Time: 24 h
Result: Reduced protein levels of tyrosinase, MITF, TRP-1, and TRP-2 in a concentration-dependent manner, with significant decreases observed at all tested concentrations.
Significantly reduced phosphorylated PKA and phosphorylated CREB levels at 10 μM, while total PKA and CREB levels remained unchanged.
Significantly reduced serine 9 phosphorylation of GSK3β, β-catenin levels, and nuclear levels of MITF, phosphorylated CREB, and β-catenin at 10 μM.
Significantly increased phosphorylated ERK1/2 levels at 10 μM, while phosphorylated p38 and phosphorylated JNK levels remained unchanged.

ELISA Assay

Cell Line: α-MSH-stimulated B16F10 murine melanoma cells
Concentration: 1, 5 and 10 μM
Incubation Time: 24 h
Result: Reduced cAMP levels in a concentration-dependent manner, with significant reduction observed at all tested concentrations.

Cell Cytotoxicity Assay

Cell Line: human chronic myelogenous leukemia K562 cells
Concentration: 50, 100, 200, 400, and 800 μg/mL
Incubation Time: 48 h (after initial 24 h seeding incubation)
Result: Exhibited cytotoxicity index percentages of 21%, 41%, 48%, 57%, and 62% at concentrations of 50, 100, 200, 400, and 800 μg/mL, respectively.
Reached a median growth inhibitory IC50 value of 220 μg/mL.
体内研究
(In Vivo)

Myricetin 3-O-galactoside (25-50 mg/kg; p.o.; 10 days) 可通过降低细菌载量、减轻组织损伤、抑制炎症反应及恢复氧化应激稳态,有效缓解小鼠的急性尿路感染。
Myricetin 3-O-β-galactoside (0.26-0.78 mg/kg; p.o.; 单次给药) 可在瑞士小鼠中产生剂量依赖性的镇痛 (ID50 = 0.26 mg/kg) 和抗炎作用,其机制为外周抑制一氧化氮合成 (主要是 iNOS),且不涉及阿片能系统或中枢镇痛活性,对运动功能也无影响。
Myricetin 3-O-β-galactoside (0.78 mg/kg; p.o.; 单次给药) 可通过 iNOS 依赖的机制在雄性 C57BL/6J 野生型小鼠中产生显著的镇痛和抗炎作用。
Myricetin 3-O-β-galactoside (0.78 mg/kg; p.o.; 单次给药) 在雄性 C57BL/6J iNOS-/- 小鼠中无镇痛或抗炎作用,证实其活性依赖于 iNOS。

Animal Model: C57BL/6 (6-week-old female)
Dosage: 25 mg/kg; 50 mg/kg
Administration: p.o.; pre-treatment for 5 days plus 5 days
Result: Alleviated UPEC-induced weight loss in mice.
Significantly reduced bacterial loads in bladder, kidney, and urine tissues, and lowered bacterial 16S rRNA expression in kidney and bladder tissues compared to the model group (25 mg/kg).
Reduced bladder bacterial load to levels comparable to the positive control, significantly lowered kidney bacterial load and urine bacterial counts by day 5 post-inoculation, and reduced bacterial 16S rRNA expression in kidney and bladder tissues compared to the model group (50 mg/kg).
Restored bladder, kidney, and spleen organ indices to near-normal levels, reduced inflammatory cell infiltration and edema in bladder and kidney tissues, and lowered bladder and kidney pathological damage scores compared to the model group (both doses).
Significantly downregulated kidney mRNA expression of proinflammatory cytokines TNF-α, IFN-γ, IL-1β, and IL-6 compared to the model group (both doses).
Restored renal CAT and SOD2 protein expression to near-normal levels, and downregulated UPEC-induced overexpression of renal HO-1 protein compared to the model group (both doses).
Did not cause significant alterations in serum liver (ALT, AST, GGT, TP) or kidney (UREA) function indices; restored UPEC-reduced serum ALB levels to near-normal (50 mg/kg).
Animal Model: Swiss mice (male, 20-30 g); iNOS-/- mice
Dosage: 0.26 mg/kg; 0.78 mg/kg
Administration: p.o.; single dose; 60 minutes pre-stimulus
Result: Significantly reduced licking time in the inflammatory (15-30 minute) phase of formalin test, with an ID50 of 0.26 mg/kg for this effect.
Significantly reduced nitrite concentrations in formalin-injected paw tissue compared to vehicle controls.
Significantly reduced paw edema AUC in carrageenan-induced edema model compared to vehicle controls.
Reduced licking time in inflammatory formalin phase and paw edema AUC in wild-type mice at 0.78 mg/kg, but had no effect in iNOS-/- mice.
Produced enhanced antinociceptive effect in formalin inflammatory phase when co-administered with aminoguanidine.
Had antinociceptive effect in formalin inflammatory phase reversed by L-arginine co-administration; D-arginine had no reversing effect.
Showed antinociceptive effect in formalin inflammatory phase not reversed by naloxone pretreatment.
Did not alter motor performance in rotarod test at any time point.
Did not affect tail-flick reflex latency, indicating no central analgesic effect.
Animal Model: C57BL/6J wild-type mice (male, 6 months old, 20-30 g)
Dosage: 0.78 mg/kg
Administration: p.o.; single dose; 60 minutes pre-stimulus
Result: Significantly reduced licking time in the inflammatory phase of formalin test compared to vehicle controls.
Significantly reduced carrageenan-induced paw edema AUC compared to vehicle controls.
Animal Model: C57BL/6J iNOS-/- mice (male, 6 months old, 20-30 g)
Dosage: 0.78 mg/kg
Administration: p.o.; single dose; 60 minutes pre-stimulus
Result: Did not reduce licking time in the inflammatory phase of formalin test compared to vehicle controls.
Did not reduce carrageenan-induced paw edema AUC compared to vehicle controls.
性状 固体
颜色 White to off-white

化学信息

分子量 480.38
分子式 C21H20O13
CAS No. 15648-86-9
别名 杨梅素 3-O-半乳糖苷

储存&溶解度

储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (104.08 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.0817 mL10.4084 mL20.8169 mL52.0421 mL
5 mM0.4163 mL2.0817 mL4.1634 mL10.4084 mL
10 mM0.2082 mL1.0408 mL2.0817 mL5.2042 mL
15 mM0.1388 mL0.6939 mL1.3878 mL3.4695 mL
20 mM0.1041 mL0.5204 mL1.0408 mL2.6021 mL
25 mM0.0833 mL0.4163 mL0.8327 mL2.0817 mL
30 mM0.0694 mL0.3469 mL0.6939 mL1.7347 mL
40 mM0.0520 mL0.2602 mL0.5204 mL1.3011 mL
50 mM0.0416 mL0.2082 mL0.4163 mL1.0408 mL
60 mM0.0347 mL0.1735 mL0.3469 mL0.8674 mL
80 mM0.0260 mL0.1301 mL0.2602 mL0.6505 mL
100 mM0.0208 mL0.1041 mL0.2082 mL0.5204 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础